A5054670872- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Colorectal Cancer Screening and Detection
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Ovarian cancer diagnosis and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple and Secondary Primary Cancers
- Acute Myeloid Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Lipids, and Metabolism
- North African History and Literature
- Cancer Research and Treatments
- Intraperitoneal and Appendiceal Malignancies
- Economic and Financial Impacts of Cancer
- Lymphoma Diagnosis and Treatment
Institut Hospitalier Franco Britannique
2016-2025
Hôpital Saint-Antoine
2012-2023
Sorbonne Université
2012-2023
Hôpital Lyon Sud
2000-2023
Centre Hospitalier René-Dubos
1999-2023
Clinique Saint Jean
2003-2023
Fondation ARCAD
2020-2023
International Drug Development Institute (Belgium)
2003-2023
Centre Jean Bernard
2003-2023
Assistance Publique – Hôpitaux de Paris
2007-2020
PURPOSE: In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to standard North Central Cancer Treatment Group/Mayo Clinic 5-day 5FU/LV regimen. This phase III investigated effect combining oxaliplatin with LV5FU2, progression-free survival as primary end point. PATIENTS AND METHODS: Four hundred twenty previously untreated patients measurable disease were...
The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy this combination in patients with metastatic colorectal cancer. We evaluated FL oxaliplatin postoperative setting.We randomly assigned 2246 who had undergone curative resection for stage II or III to receive alone six months. primary end point was disease-free survival.A total 1123 were each group. After a median follow-up 37.9 months, 237 group given cancer-related event,...
In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination irinotecan or oxaliplatin over FU + LV alone. This study investigated two sequences: folinic acid, FU, and (FOLFIRI) followed by (FOLFOX6; arm A), FOLFOX6 FOLFIRI (arm B).
PURPOSE Three-year disease-free survival (DFS) was significantly improved in patients who had undergone resection with curative intent for stage II or III colon cancer received bolus plus continuous-infusion fluorouracil leucovorin (LV5FU2) the addition of oxaliplatin (FOLFOX4). Final results study, including 6-year overall (OS) and 5-year updated DFS, are reported. PATIENTS AND METHODS A total 2,246 were randomly assigned to receive LV5FU2 FOLFOX4 6 months. The primary end point DFS....
Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given promising phase II results obtained with Gem-oxaliplatin (GemOx) combination, we conducted a III study comparing GemOx Gem alone in cancer.Patients cancer were stratified according to center, performance status, and type of disease (locally v metastatic) randomly assigned either (gemcitabine 1 g/m2 as 100-minute infusion on day oxaliplatin 100 mg/m2 2-hour 2 every weeks) or weekly 30-minute infusion).Three...
PURPOSE This multicenter study compared the therapeutic ratio of a monthly schedule low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with bimonthly high-dose LV 5-FU plus continuous infusion in patients advanced colorectal cancer. PATIENTS AND METHODS Of 448 randomly assigned to treatment, 433 were assessable. Treatment A was regimen intravenous (IV) 20 mg/m2 425 for 5 days every 4 weeks. B IV 200 as 2-hour followed by 400 22-hour 600 2 consecutive Therapy continued until disease...
In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is standard first-line regimen. The cumulative neurotoxicity often requires therapy to be stopped in patients who are still responding. This study evaluates new strategy intermittent treatment that based on FOLFOX7, simplified regimen high-dose oxaliplatin.Previously untreated were randomly assigned either FOLFOX4 administered every 2 weeks until progression (arm A) or FOLFOX7...
Purpose A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. shorter-term providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice. Methods Individual patient data were pooled from 18 randomized phase III cancer trials. Trials included 43 arms, a sample size 20,898 patients. The primary hypothesis was that disease-free (DFS), 3 follow-up, an...
Limited data are available on the time course of treatment failures (recurrence and/or death), nature and duration adjuvant benefit, long-term recurrence rates in patients with resected stage II III colon cancer.
Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall (OS) benefit adjuvant oxaliplatin stage II to III resected colon cancer. This update presents 10-year OS DFS by mismatch repair (MMR) status BRAF mutation. Methods Survival actualization after follow-up was performed 2,246 patients with We assessed MMR mutation 1,008 formalin-fixed...
The management of locally advanced (LA) pancreatic cancer patients remains controversial. To select who could benefit from chemoradiotherapy (CRT), the therapeutic strategy used by Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) consisted initial chemotherapy (CT) for at least 3 months. decision to administer CRT or continue CT in nonprogressive was investigator's choice.Retrospective analysis outcome 181 with LA (76 women and 105 men; mean age, 61 years; range, 37 85 years)...
Abstract An international panel of multidisciplinary experts convened to develop recommendations for the management patients with liver metastases from colorectal cancer (CRC). The aim was address main issues facing CRC hepatobiliary team (MDT) when managing such and standardize treatment receive in different centers. Based on current evidence, group agreed a number including following: (a) primary is achieving long disease-free survival (DFS) interval following resection; (b) assessment...
Purpose Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced resected colorectal cancer. This analysis compares the safety efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients age younger than at least 70 years. Patients Methods retrospective included 3,742 cancer (614 ≥ 70) from four clinical trials testing FOLFOX4 adjuvant, first-, second-line settings. End points grade 3 adverse events, response rate (in disease),...
Purpose This study compared chemotherapy discontinuation with maintenance therapy leucovorin and fluorouracil after six cycles of folinic acid, fluorouracil, oxaliplatin (FOLFOX) in the first-line treatment metastatic colorectal cancer. Patients Methods Two hundred two patients untreated cancer were randomly assigned to receive modified FOLFOX7 (mFOLFOX7) followed by simplified plus bolus infusional until progression (arm 1 or arm, n = 98) mFOLFOX7 before a complete stop 2 chemotherapy-free...
Oxaliplatin combined with fluoropyrimidine improves survival in patients stage III colon cancer. However, adjuvant chemotherapy oxaliplatin is controversial II and elderly patients.We performed subgroup analyses of randomly assigned fluorouracil leucovorin (FL) ± (FOLFOX4) the Multicenter International Study Oxaliplatin/Fluorouracil/Leucovorin Adjuvant Treatment Colon Cancer study. Comorbidities, severe adverse events, second cancers, management relapse death as a result causes than other...
This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, oxaliplatin [FOLFOX-4]) in first-line treatment epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC).The activity plus was colon cell lines xenograft models. In clinical study, patients mCRC received on day 1 a 14 cycle, (initial dose 400 mg/m(2) during week 1, then 250 weekly) followed by FOLFOX-4...
Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) are now standard. We examined the impact age on recurrence mortality after these newer options. Patients Methods analyzed 11,953 < 70 2,575 ≥ years seven trials comparing IV FU fluoropyrimidines (capecitabine, uracil, or tegafur) combinations oxaliplatin...
In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination irinotecan or oxaliplatin over FU + LV alone. This study investigated two sequences: folinic acid, FU, and (FOLFIRI) followed by (FOLFOX6; arm A), FOLFOX6 FOLFIRI (arm B).